One sentence summary: Supplementation with high-dose vitamin D in older people for 12 months in a randomised, placebo-controlled trial had no significant effect on gene expression or on plasma concentrations of cytokines.
Introduction
Randomised controlled trials afford reliable approaches to understand the causal relevance of drug treatments and can also help our understanding of disease mechanisms by relating changes in biomarkers with incidence of disease or with surrogate markers of disease.
Advances in molecular methods now permit use of high-throughput functional genomics strategies in clinical trials. Application of such approaches has been under-utilised to date, with previous studies focusing on comparisons of transcriptomes to understand mechanisms and identify novel biomarkers (1) . Animal and experimental models of disease pathogenesis have limited ability for translation into humans, particularly in the context of complex diseases (2, 3) , while incomplete knowledge of mechanisms contributes to inconclusive findings in randomised trials and the current high failure rate in late stage drug development. Hence, there is an urgent need to demonstrate the likely significant value in combining functional genomic approaches such as genome-wide genotyping and gene expression profiling together with biochemical and clinical markers in clinical trials to enhance our understanding of pathophysiological processes and mechanisms of action of novel drug treatments. Such approaches may also allow high-throughput assessment of cellular and molecular responses at group and individual levels that can also be integrated with effects on clinical outcomes data. Hence, integrated analysis may yield clinically relevant insights about treatment that could guide the design of large outcome trials. The aim of the work described here was to examine the molecular responses to vitamin D supplementation in a randomised, placebo-controlled trial. To achieve this, we investigated changes in response to treatment after 12 months in whole blood transcriptomes and plasma levels of cytokines, in addition to genetic determinants of individual responses on 
Results

Effects of vitamin D supplementation on gene expression
Following sample processing and quality control, genome-wide gene expression data on 16,760 probes (12,910 genes) were available for 298 of 305 participants who were randomised to the trial (560 samples, of which 262 had both baseline and 12 month samples) (Figure 1 ). The mean age of study participants was 72 years at randomisation, 51% were male and 12% reported prior use of vitamin D supplements (£400 IU of vitamin D 3 daily) (9) . Compliance with instructions to take vitamin D supplements or placebo was high, with 90% (4000 IU), 92% (2000 IU) and 85% (placebo) reporting taking the capsules on all or most days at 12 months (8, 9 Figure 2A and Supplementary Figures 3-6 ). The top 100 PCs accounted for 60% of the total variance (Supplementary Figure 3 ).
We next formally tested the effects of vitamin D supplementation on genome-wide gene expression considering significantly differentially expressed probes at an FDR <5% for any fold change in an unadjusted model. As expected after successful randomisation, we did not observe any significant differences in gene expression when comparing allocation groups at baseline (placebo baseline, 2000 IU baseline and 4000 IU baseline) (Supplementary Table 1 ).
The pre-defined primary outcome sought to determine differences in gene expression in response to any dose of vitamin D compared with placebo. We compared differences in transcriptome among participants allocated to vitamin D (4000 IU or 2000 IU) at 0 vs 12 months versus those allocated to placebo. Difference in difference analysis was estimated using (expression gene A following vitD 12months -expression gene A vitD baseline ) -(expression gene A placebo 12months -expression gene A placebo baseline ). We found that 375 probes (for 4000 IU minus placebo using the difference in difference estimate as above) and 329 probes (for 2000 IU minus placebo) were significantly differentially expressed following vitamin D supplementation (unadjusted p-value <0.05), but none remained significant after taking account of multiple comparisons (FDR <5%) (Supplementary Table 1 Table 1 ). However, neither of these analyses took account of the differences in the placebo group and, hence, were less robust than the analyses of differences and random-effects detailed above. These results would thus require validation in larger studies with similar design.
We hypothesised that differences in transcriptomes would be more evident when Table 1) . We repeated such comparisons using subsets with paired samples before and after treatment among individuals who at baseline were deficient (<50 nmol/L and separately for those with <25 nmol/L), but did not detect any significant differences in either subgroup (FDR <5%, Supplementary Table 1) . Finally, although we did not pre-specify it, we selected individuals whose change (delta) in vitamin D levels was high (vitD 12months -vitD baseline ), regardless of allocated treatment. Although this analysis is more likely to be confounded it provided more power as more individuals with greater differences in plasma vitamin D in response to supplementation were included. We chose the median (+44.79 nmol/L) as this yielded the highest change in the maximum number of individuals (n=145). As expected, none of the placebo group had a difference of this magnitude (median: +2.58 nmol/L). In paired analysis we found five genes significantly different at an FDR of <5% (Supplementary Table 1 ), but the effect sizes for these genes were small (fold change range: 0.81 -1.12) and further work is needed to replicate such associations in other trial populations.
Individual responsiveness to vitamin D supplementation: impact of genotype
This study lacked power to assess differences in the effects of treatment with vitamin D by differences in genome-wide genetic variation. We restricted our analysis to SNPs with prior evidence of association with plasma 25(OH) D levels from population GWAS (10) (rs12794714, rs2282679, rs7041 and rs7944926) for which we had genotyping data available. Previous studies in twins suggested that summer levels of vitamin D were not strongly influenced by genetic variation (11, 12) . Our pre-specified analysis assessed the hypothesis that genotype may modulate the response to vitamin D supplementation. We analysed vitamin D levels following treatment with measurements at 6 and 12 months, Table 2 ). At high dose (4000IU), we found no significant effects of rs7041 (or other SNPs). Although higher doses may abrogate the genetic effect, better powered studies are needed to confirm this hypothesis.
We next considered whether there was evidence that genetic determinants of gene expression were modulated by supplementation with vitamin D by adopting a genetical genomics approach. Genetic variation is known to be an important determinant of individual gene expression and to be highly context-specific (13) . We hypothesised that genetic variation may be an important contributor to individual gene expression differences in response to vitamin D. Although our study did not detect differences in gene expression after supplementation, we carried out an expression quantitative trait analysis as prespecified given that individual level effects on gene expression dependent on genotype may still occur. Following sample processing and quality control, we analysed genotyping data on 497,136 variants for 288 individuals. We tested for evidence of association with gene expression using an additive linear model for 14,972 probes, including the top principal components as covariates after maximising for cis-eQTLs in each group (see Methods).
We defined expression associated SNPs (eSNPs) as cis-eSNPs (those located within 1Mb of the gene expression probe) or trans-eSNPs (located >1Mb of the gene expression probe).
At baseline, we found 31,568 cis-eQTLs and 34,254 at 12-months (unique SNP-probe pairs, 2000 IU and 4000 IU groups jointly to maximise sample size, FDR <5%) (Supplementary Table 3 ). There was a significant and positive overlap with comparable previously published data for whole blood eQTL (14) indicating high reproducibility despite large differences in sample size (1.75 fold-change overlap, q-value <0.001). To investigate response eQTLs present in samples from vitamin D supplemented individuals, we performed an analysis that took into account both effect size (gene expression differences) and statistical significance by obtaining eQTLs from the fold changes between treated (joint 2000 IU and 4000 IU 12 months' supplementation) and their baseline values after correcting for principal components as outlined above. We found no significant associations involving response eQTLs (FDR <10%, Supplementary Table 3 , Supplementary Figure 8) .
Changes in plasma cytokine concentrations following vitamin D supplementation
In addition, we assessed whether supplementation with vitamin D had any significant effect on plasma levels of cytokines (Table 1) Table 4) .
Discussion
Overall, the present study demonstrated that allocation to high-dose oral vitamin D 3 in 305 older people had no significant effect on gene expression or plasma levels of cytokines when measured after 12 months despite achieving significantly higher plasma 25(OH)D levels (8) . To our knowledge, this is the first randomised, placebo-controlled trial that assessed molecular changes and genetic effects following vitamin D supplementation.
Previous studies lacking appropriate randomization or use of placebo controls may have been confounded by time. Both seasonal and age related effects on gene expression have been reported previously (16, 17) . Careful design and analysis are required; data analysis protocols can be pre-specified with blinding maintained. We demonstrated no significant 
Materials and Methods
Details
Procedures
Briefly, a research nurse visited participants at their homes to obtain medical history, samples and measurements. PAXgene Blood RNA tube (Qiagen) were used to ensure RNA stability without needing immediate processing. Biological samples were transported at 2-4°C and then stored at -80°C. RNA and DNA samples were processed at the end of the study as detailed below. Plasma 25(OH)D levels were measured using an Access 2 immunoassay analyser (Beckman Coulter Ltd., High Wycombe, England) complying with the quality assurance DEQAS scheme. Further details have been described previously (8) .
Plasma cytokines were measured using a MesoScale Discovery multi-spot assay system. The V-Plex pro-inflammatory panel 1 kit was used, with detection antibodies for interferon-gamma (IFN-γ), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10) and tumour necrosis factor alpha (TNF-α). In brief, assays were sandwich electrochemiluminescence (ECL) immunoassays. Between-run precision over the experiment for IFN-γ was 11.39% at 91.78 pg/mL and 10.73% at 10.73 pg/mL; for IL-4 12.99% at 11.35 pg/mL and 14.95% at 2.53 pg/mL; for IL-6 11.15% at 49.20 pg/mL and 13.02% at 8.85 pg/mL; for IL-8 9.38% at 32.67 pg/mL and 12.76% at 6.75 pg/mL; for IL-10 13.60% at 22.01 pg/mL and 13.82% at 4.49 pg/mL; and for TNF-α 12.29% at 11.15 pg/mL and 14.36% at 3.19 pg/mL.
DNA extraction and genotyping
Genomic DNA was extracted from the buffy coat layer using DNeasy Blood and Tissue Kit (Qiagen), and quantified by NanoDrop (Thermo Fisher Scientific; Waltham, MA) and Agilent 2100 Bioanalyzer (Agilent Technologies). 299 samples (of 305 possible) were available for DNA isolation and were processed over a single batch. Genotyping was performed using the Illumina Infinium HumanOmniExpress-24v1-0 (Illumina) beadchips following the Infinium HTS protocol (Illumina) at the Oxford Genomics Centre (WTCHG). Sample concentration was measured using PicoGreen (Thermo Fisher Scientific) and normalised. In total, 716,503 single nucleotide polymorphisms (SNPs) were genotyped. The genotype call rate cut-off was <98%. The overall call rate was 99.75% with one sample removed at this stage (genotype call rate 96.8%).
RNA extraction, cDNA conversion and microarray measurements
Total RNA was isolated from whole blood samples using PAXgene Blood RNA Kit (Qiagen) with recovery of RNA populations of <200 nucleotides and globin messenger RNA clearance using the GLOBINclear Kit (Ambion). Quantification of RNA and quality measures were assessed using Agilent 2100 Bioanalyzer (Agilent Technologies) and Nanodrop (Thermo Fisher Scientific). Complementary DNA synthesis, labelling and microarray hybridisation were performed at the Oxford Genomics Centre using Illumina Human-HT-12v4 expression BeadChip (Illumina). In total, 574 samples were available for further processing after microarray measurements (of 610 possible from the 305 participants who completed the study). Thirty samples were not available at end of study, four samples failed RNA quality metrics before array hybridisation and two during array processing. Three additional samples were identified as of low quality due to low amounts of complementary RNA upon further inspection. Arrays were run in batches of 96 randomised samples.
Statistical analysis
A priori power for detecting gene expression differences
Statistical power calculations for gene expression analysis for in vivo studies are not well documented. We estimated statistical power using available data from vitamin D treated human cell line experiments (7, 19) . We estimated that vitamin D 3 supplementation may alter gene expression by 1.5 to 3-fold differences. Sample size was prioritised for the main trial outcomes (circulating levels of 25(OH)D). With a fixed sample size of 100 per group for the BEST-D trial, taking a two-sided alpha of 0.05 t-test, beta of 10%, standard deviation of 0.7, and equal size group we estimated we would be able to detect effect size differences of 1.25-fold change. Calculations were performed using the base package in R and pwr (v1.1-3).
Genome-wide SNP processing and statistical analysis
Quality control was carried out using standard approaches (20, 21) and included assessment of gender miss-identification; subject relatedness, duplication and divergent ancestry; individuals with elevated missing data rates or outlying heterozygosity rate; identification of markers (SNPs) with excessive missing data rates; identification of differing genotype call rates between groups; SNP quality (filtering of monomorphic SNPs, SNPs with missing values or nonsense values; low call rate; violation of Hardy-Weinberg equilibrium; duplication; and minimum allele frequency). We removed low quality markers followed by individuals. We excluded non-autosomal variants. We used the following criteria for filtering: call rates >98%; minor allele frequency (MAF) >10%; Hardy-Weinberg equilibrium threshold of 1x10 -6 . This resulted in 19 SNPs with a significantly different (pvalue <0.01) missing data rate between cases and controls (treated vs placebo) being excluded; 4,893 variants due to missing genotype data; 20 variants due to Hardy-Weinberg equilibrium and 193,723 with MAF <10%. In total, 497,136 variants passed QC filters. Of 299 genotyped individuals, eleven were excluded after QC: one individual was excluded due to low genotype call rate (<98%); two due to gender misidentification; two due to relatedness (identity-by-descent value >0.1875); three due to ancestry other than Caucasian, and three due to a high genotype failure rate (³0.03) and/or a heterozygosity rate ±3 SD from the mean (Supplementary Figure 1) .
Linear regression association tests were conducted using frequentist methods with PLINK version 1.90 (22) . We corrected for baseline vitamin D circulating levels, vitamin D intake (assessed at baseline), season (based on date of trial recruitment), gender, age, baseline BMI, medical history (incident fracture, incident respiratory infection, diabetes, heart disease, chronic obstructive pulmonary disease, asthma) and current smoking status. To explore genetic determinants of vitamin D levels we only considered SNPs previously identified by GWAS (10) and which were included in the genotyping array (rs12794714, rs2282679, rs7041 and rs7944926). We utilised an adaptive Monte Carlo permutation as implemented by PLINK to derive empirically determined significance values.
Quality control, normalisation of microarray data and differential gene expression analysis
Quality assessment of gene expression data included visual analysis of un-normalised data;
analysis of built-in control probes; sample outlier detection and estimation of the proportion of probes expressed across samples (23) (Supplementary Figure 2) . Outlier detection was carried out using ArrayQualityMetrics v3.24.0 (24). We removed samples that failed three criteria based on the package's internal scores of individual array quality, homogeneity between arrays and between array comparisons. We found that 11 samples were classed as outliers by all three methods. Outlier thresholds (sum of the distances to all other arrays, Kolmogorov-Smirnov statistic Ka and Hoeffding's statistic Da) were calculated by the package based on the array signal intensity values.
We excluded probes not expressed in at least three arrays with detection p-values <0.05.
Pre-processing and probe filtering included background correction as described in (25) using built-in negative controls and VSN normalisation. Figure 4 ). Principal components analysis was performed with R's prcomp function with scaling and centring.
We performed differential expression comparisons using limma v3.24.15 with linear models fit with empirical Bayes analysis (26) . The primary comparison was a difference
in difference estimator. We tested for linear or quadratic effects of vitamin D on expression and on the absolute change in expression. We also performed a linear mixed model analysis with the R package lmerTest (27) , using person-specific random effects to account for between-person expression heterogeneity and fixed effects for time and time interacted with vitamin D levels.
Expression quantitative trait loci (eQTL) analysis
We used an additive linear model as implemented in the R package MatrixEQTL v2. permutations to obtain empirical p-values.
Statistical analysis of circulating cytokines
We imputed missing data using multiple imputation methods with 50 datasets, a maximum iteration of 50 and predictive mean matching (R packages mice v2.30 and miceadds v2. 
